000			03780nam a22005897a 4500
008			171220s20182018 xxu||||| |||| 00| 0 eng d
022			_a1068-9265
040			_aOvid MEDLINE(R)
099			_a29238881
245			_aPeritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
251			_aAnnals of Surgical Oncology. 25(4):1094-1100, 2018 Apr.
252			_aAnn Surg Oncol. 25(4):1094-1100, 2018 Apr.
253			_aAnnals of surgical oncology
260			_c2018
260			_fFY2018
266			_d2017-12-20
501			_aAvailable online from MWHC library: 1994 - present
520			_aCONCLUSION: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of urachus origin, especially when complete CRS is achieved.
520			_aMETHODS: A prospective multicenter international database was retrospectively searched to identify all patients with urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed.
520			_aPURPOSE: Peritoneal carcinomatosis or pseudomyxoma peritonei from urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment.
520			_aRESULTS: The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4-30.5, p < 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications.
546			_aEnglish
650			_a*Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
650			_a*Chemotherapy, Cancer, Regional Perfusion/mo [Mortality]
650			_a*Cytoreduction Surgical Procedures/mo [Mortality]
650			_a*Hyperthermia, Induced/mo [Mortality]
650			_a*Neoplasm Recurrence, Local/th [Therapy]
650			_a*Peritoneal Neoplasms/th [Therapy]
650			_a*Urachus/pa [Pathology]
650			_aAdult
650			_aCombined Modality Therapy
650			_aFemale
650			_aFollow-Up Studies
650			_aHumans
650			_aInternational Agencies
650			_aMale
650			_aMiddle Aged
650			_aNeoplasm Recurrence, Local/pa [Pathology]
650			_aPeritoneal Neoplasms/sc [Secondary]
650			_aPrognosis
650			_aProspective Studies
650			_aRegistries
650			_aRetrospective Studies
650			_aSurvival Rate
650			_aYoung Adult
651			_aWashington Cancer Institute
657			_aJournal Article
700			_aSugarbaker, Paul H
790			_aBartlett DL, Glehen O, Goere D, Levine EA, Marolho C, Mercier F, Passot G, PSOGI and BIG RENAPE Groups, Sugarbaker PH, Villeneuve L, Yonemura Y
856			_uhttps://dx.doi.org/10.1245/s10434-017-6299-z _zhttps://dx.doi.org/10.1245/s10434-017-6299-z
942			_cART _dArticle
999			_c2926 _d2926